STOCK TITAN

Sensus Healthcare Inc - SRTS STOCK NEWS

Welcome to our dedicated page for Sensus Healthcare news (Ticker: SRTS), a resource for investors and traders seeking the latest updates and insights on Sensus Healthcare stock.

Overview of Sensus Healthcare Inc

Sensus Healthcare Inc is a specialized medical device company that has dedicated over a decade to the development of non-invasive treatment solutions using proprietary superficial radiation therapy (SRT) technology. This innovative treatment method is designed for both oncological and non-oncological skin conditions, including various forms of non-melanoma skin cancers and conditions such as keloids, offering a safe and cost-effective alternative to surgical procedures.

Core Technology and Treatment Solutions

The company utilizes a proprietary low energy x-ray radiation system that underpins its SRT technology. This method enables precise targeting of skin lesions while minimizing damage to surrounding tissues. The approach is rooted in extensive research and development, ensuring that each device deployed not only aligns with current clinical standards but also supports a streamlined treatment process. The primary devices in the company’s portfolio are designed to simplify the treatment procedure while ensuring efficacy and patient safety.

Business Model and Revenue Generation

Sensus Healthcare Inc generates revenue primarily through the sale of its specialized SRT treatment devices alongside an associated service program. The revenue model is based on direct transactions with hospitals, oncology centers, and dermatology practices, particularly in the United States. The company’s sales approach integrates product delivery with ongoing support, positioning Sensus as a comprehensive service provider within the medical device industry. This dual-focus on advanced technology and customer service ensures that clients receive not only the equipment but also the necessary operational expertise to maximize treatment outcomes.

Market Position and Industry Significance

Operating within the competitive realm of medical devices, Sensus Healthcare Inc has carved out a niche by focusing on non-invasive superficial radiation therapy. The technology addresses a clear need in the treatment of skin conditions by reducing the potential risks and complications associated with more invasive procedures. With increasing emphasis on patient safety and cost-effectiveness in healthcare, the company’s offerings are well-positioned to provide value within hospital oncology and dermatology departments. Its emphasis on targeted radiation treatment distinguishes its operational approach from other modalities available in the market.

Operational Focus and Customer Base

The company's operational framework is built around delivering effective treatment solutions through both its high-quality devices and a robust support program. The customer base includes major healthcare providers such as hospital oncology departments and specialized dermatology practices. By prioritizing reliability and clinical efficacy, Sensus Healthcare sustains trust within the medical community, ensuring continuous adoption of its technology in outpatient treatment settings.

Clinical Impact and Safety

At the heart of Sensus Healthcare Inc's offerings is a strong commitment to patient safety and treatment efficacy. The non-invasive SRT technique minimizes the need for surgical intervention, thereby reducing recovery times and potential risks associated with more invasive treatments. This clinical approach not only enhances patient outcomes but also supports operational efficiency in healthcare settings by offering a streamlined alternative that aligns with modern treatment protocols.

Competitive Landscape and Differentiation

Sensus Healthcare Inc operates in a dynamic industry where differentiation is critical. The company sets itself apart through its exclusive focus on superficial radiation therapy, a technology with a clear evidential basis in decades of research and clinical application. Although facing competition from traditional and emerging treatment modalities, Sensus leverages its research-backed technology and dedicated service programs to maintain a distinct foothold in the market. Expertise in both technological innovation and customer service elevates its competitive profile as a trusted provider in the non-invasive medical device segment.

Conclusion

In summary, Sensus Healthcare Inc is a specialized medical device entity that combines technological innovation with secure, non-invasive treatment options. Its use of superficial radiation therapy not only underscores advances in medical device innovation but also reflects the company's commitment to enhancing patient care in the treatment of skin conditions. This comprehensive approach, integrating advanced product development with dedicated service programs, positions Sensus Healthcare as a valued participant in a complex and critical segment of healthcare technology.

Rhea-AI Summary

Sensus Healthcare (Nasdaq: SRTS), a medical device company focused on non-invasive treatments, announces its upcoming Third Quarter 2024 financial results conference call scheduled for November 14, 2024, at 4:30 p.m. Eastern time. Management will discuss Q3 2024 financial results, provide business updates, and review recent and upcoming milestones. The call will be accessible via pre-registration or direct dial-in, with a replay available until December 14, 2024. A webcast will also be available through the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.19%
Tags
conferences earnings
-
Rhea-AI Summary

Sensus Healthcare (Nasdaq: SRTS) has shipped an SRT system to Providence Swedish Hospital in Seattle, marking its latest success in expanding to community hospital oncology departments. The sale highlights growing interest in superficial radiotherapy (SRT) for treating non-melanoma skin cancer and keloids on an outpatient basis.

Dr. Christopher Loiselle, Medical Director of Radiation Oncology at Swedish Cancer Institute, praised the SRT system as state-of-the-art for treating skin cancers and other superficial conditions. Joe Sardano, CEO of Sensus Healthcare, expressed delight in Providence Swedish Hospital's recognition of SRT benefits and noted increasing inquiries from hospitals nationwide about offering non-invasive skin cancer treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.95%
Tags
none
-
Rhea-AI Summary

Sensus Healthcare (SRTS) reported strong Q2 2024 financial results, with revenues doubling to $9.2 million compared to Q4 2023. The company achieved net income of $1.6 million ($0.10 per diluted share) and positive Adjusted EBITDA of $2.1 million. Key highlights include:

- Shipped 23 systems, including 3 SRT-100 units to Asia
- Signed 15 'Fair Deal Agreements' for SRT-100 Vision units
- Ended Q2 with $19 million in cash and no debt
- Accounts receivable increased to $18.3 million

The company's growth was driven by higher superficial radiotherapy unit sales and international expansion efforts, particularly in Asia. Management expects the Fair Deal Agreement program to generate recurring revenue starting in 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.43%
Tags
Rhea-AI Summary

Sensus Healthcare (Nasdaq: SRTS) has announced a conference call scheduled for Thursday, August 8, 2024, at 4:30 p.m. Eastern time to discuss its second quarter 2024 financial results and provide a business update. The company, which specializes in non-invasive treatments for oncological and non-oncological conditions, encourages participants to pre-register for the call. Those unable to pre-register can dial in directly. The call will also be webcast live and accessible through the company's website. A telephone replay will be available until September 8th, and an archived webcast will be accessible in the Investor Relations section of the website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.84%
Tags
conferences earnings
-
Rhea-AI Summary

Sensus Healthcare (Nasdaq: SRTS), a medical device company specializing in non-invasive treatments for oncological and non-oncological conditions, has announced its upcoming second quarter 2024 financial results and business update conference call. The call is scheduled for Thursday, August 8, 2024, at 4:30 p.m. Eastern time.

Key points:

  • Management will discuss Q2 2024 financial results
  • A business update and discussion on recent and upcoming milestones will be provided
  • Participants can pre-register for the call or dial in directly
  • A webcast will be available on the company's Investor Relations website
  • A telephone replay will be accessible until September 8th
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.1%
Tags
conferences earnings
-
Rhea-AI Summary

Sensus Healthcare reported a strong first-quarter financial performance with revenues up over three-fold compared to the previous year. Revenues were $10.7 million, net income was $2.3 million, and adjusted EBITDA was $3.0 million. The company launched a recurring revenue program, the 'Fair Deal Agreement', to complement its fair market value lease program. Sensus Healthcare showcased its products at key industry events and announced significant sales and developments, including a U.S. patent for SRT-100 Vision System and international sales.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
38.85%
Tags
Rhea-AI Summary

Sensus Healthcare, Inc. announces the sale of an SRT-100 system to the Veterinary Specialist Referral Center in Tel Aviv, marking the first veterinary commercial sale of the device outside the U.S. This system will provide gentler radiotherapy to treat tumors in dogs and cats. The Knowledge Farm is the largest private Veterinary Specialty Referral Center in Israel, employing over 20 specialists and 30 veterinary technicians. The SRT-100 system has previously been acquired by Colorado State University for treating companion animals and conducting studies on equine ophthalmic tumors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
-
Rhea-AI Summary

Sensus Healthcare, Inc. announces the sale of the first SRT-100 Vision™ system in Asia to Far Eastern Memorial Hospital in Taiwan. The hospital plans to conduct research on new indications for the system, potentially leading to global label expansion. The company is optimistic about future sales in the region and emphasizes the importance of this sale. The SRT-100 Vision system utilizes image-guided ultrasound technology and has seen recent enhancements for improved clinical outcomes. Additionally, Sensus Healthcare will host a conference call on May 9, 2024, to discuss first-quarter financial results and provide business updates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.01%
Tags
none
-
Rhea-AI Summary
Sensus Healthcare, Inc. (Nasdaq: SRTS) announces a conference call on May 9, 2024, to discuss Q1 2024 financial results and business updates. Investors can pre-register for the call to receive a unique dial-in number. The call will address recent and upcoming milestones. Participants without internet access can join by phone. A webcast and replay options will be available for those unable to attend the live call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
Rhea-AI Summary
Sensus Healthcare, Inc. (Nasdaq: SRTS) will host a conference call on May 9, 2024, to discuss the financial results for the first quarter of 2024, provide a business update, and discuss recent and upcoming milestones. Participants can pre-register for the call and access it through various methods.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
conferences earnings

FAQ

What is the current stock price of Sensus Healthcare (SRTS)?

The current stock price of Sensus Healthcare (SRTS) is $4.72 as of April 1, 2025.

What is the market cap of Sensus Healthcare (SRTS)?

The market cap of Sensus Healthcare (SRTS) is approximately 77.6M.

What is the primary focus of Sensus Healthcare Inc?

Sensus Healthcare Inc specializes in developing and manufacturing non-invasive superficial radiation therapy devices for treating both oncological and non-oncological skin conditions.

How does Sensus Healthcare generate its revenue?

The company primarily generates revenue through direct sales of its specialized treatment devices and associated service programs to hospital oncology centers and dermatology practices.

What skin conditions are treated with the company's technology?

Their technology is used for treating non-melanoma skin cancers such as basal cell and squamous cell carcinoma, as well as non-cancerous conditions like keloids.

What distinguishes Sensus Healthcare's technology from traditional treatment options?

The company’s proprietary low energy x-ray radiation system offers a non-invasive, cost-effective, and targeted approach, reducing the need for surgical interventions and minimizing damage to surrounding tissues.

Who typically uses Sensus Healthcare's treatment devices?

The primary users are hospitals, oncology departments, and dermatology practices, especially in the U.S., where the non-invasive treatment options provide significant clinical advantages.

How does Sensus Healthcare position itself against competitors?

By leveraging extensive research and a unique focus on superficial radiation therapy, Sensus Healthcare differentiates itself through its commitment to safe, efficient, and non-invasive treatment solutions that are tailored to specific skin conditions.
Sensus Healthcare Inc

Nasdaq:SRTS

SRTS Rankings

SRTS Stock Data

77.61M
13.57M
17.75%
30.71%
5.13%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
BOCA RATON